. Author manuscript; available in PMC: 2014 Jun 2.

Published in final edited form as: J Am Coll Cardiol. 2012 Oct 16;60(16):1558–1565. doi: 10.1016/j.jacc.2012.05.049

Table 2.

Univariate Analysis of Biomarkers and Stage of Hypertension

Hypertensive Stage	proBNP_1–108 Bio-Rad (� ± SE)	BNP_1–32 Shionogi (� ± SE)	BNP_1–32 Biosite (� ± SE)	NT-proBNP_1–76 Roche (� ± SE)	ANP_1–28 Phoenix Pharmaceuticals (� ± SE)	NT-ANP_1–98 Phoenix Pharmaceuticals (� ± SE)
All subjects
Normotensive	Reference	Reference	Reference	Reference	Reference	Reference
Pre-hypertensive	0.06 ±0.07	−0.00 ±0.06	−0.02 ±0.07	−0.01 ±0.07	0.02 ±0.04	−0.03 ±0.04
Stage I hypertensive	0.16 ±0.07^*	0.12 ±0.07	0.17 ±0.08^*	0.33 ±0.08^†	0.10 ±0.04^*	0.12 ±0.04^*
Stage II hypertensive	0.61 ±0.09^†	0.52 ±0.08^†	0.86 ±0.10^†	0.96 ±0.11^†	0.20 ±0.05^†	0.24 ±0.06^†

Subjects not on antihypertensive medications

Normotensive	Reference	Reference	Reference	Reference	Reference	Reference
Pre-hypertensive	0.03 ±0.07	0.04 ±0.07	−0.06 ±0.08	−0.06 ±0.08	0.02 ±0.05	−0.08 ±0.05
Stage I hypertensive	0.13 ±0.09	0.07 ±0.08	0.11 ±0.10	0.23 ±0.10^*	0.04 ±0.05	0.04 ±0.05
Stage II hypertensive	0.50 ±0.12^†	0.49 ±0.11^†	0.62 ±0.14^†	0.68 ±0.14^†	0.11 ±0.08	0.20 ±0.08^*

Values are 1 ± SE in contrast to normotensive subjects. Logarithm of BNP/ANP values used to satisfy regression assumptions.

p < 0.05,

^†

p < 0.001 compared with normotensive subjects.

Abbreviations as in Table 1.